Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

NCT02154737 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Gemcitabine
DRUG: Erlotinib

Sponsor

Tony Reid, M.D., Ph.D.

Collaborators

[object Object]